After entering the flu season
The demand for influenza medication has increased significantly
Mabaloxavir tablets
became the successor to oseltamivir
"Internet celebrity" flu medication
According to the People's ** client on the 17th, citing Red Star News, it was noted that the drug publicity of a number of public hospitals was queriedThe price of a box of mabaloxavir tablets (specification: 20mg*2 tablets) is 22236 yuan. On the online drug purchase platform, some pharmacies marked 418 yuan for the box, which was more than 87% higher than the hospital, and the single tablet was more than 200 yuan.
At present, imported mabaloxavir has been included in the National Reimbursement Drug List, and the marketing authorization holder is Roche Pharmaceutical. However, from the approval in 2021 to March this year, the age group of mabaloxavir has only been expanded to patients aged 5 years and above. Unlike oseltamivir, it has a longer half-life and only needs to be taken once.
On December 16, Song Chunlan, director of the emergency department of the South Branch of Henan Provincial Children's Hospital, remindedThe applicable patient group of mabaloxavir is restrictive, and patients diagnosed with influenza must be five years old and weigh more than 20 kg before it can be used, and it can be used if it is not a common cold.
There are pharmacies that sell more than 400 yuan for a single box
87% higher than the hospital price
Recently, under the raging influenza, a new "Internet celebrity drug" has been created - mabaloxavir.
Screenshot from an e-commerce platform.
In view of the ease of use and obvious efficacy of this drug, it has attracted more and more patients' attention. However, the high monolithic ** is also a distinctive feature of mabaloxavir.
At present, mabaloxavir has been included in the National Medical Insurance Drug List, and the medical insurance reimbursement category is medical insurance category B. Inquire about the drug publicity of many public hospitals** and note that the price of a box of mabaloxavir tablets (specification: 20mg*2 tablets) is 22236 yuan.
Screenshot of the official WeChat of the National Health Insurance Administration.
However, there are different levels of mabaloxavir on e-commerce platforms**. According to a number of online drug purchase platforms, most of the ** of a box of mabaloxavir tablets are higher than those in hospitals, and there are more pharmacies with a price of about 300 yuan. Among them, the price of pharmacies reached 418 yuan, which was more than 87% higher than that of hospitals, and the price of a single tablet exceeded 200 yuan.
From the point of view of the applicable patient population,The drug has been on the market for a relatively short time in China, and there is a lack of clinical trial data for some ages, and it has not been approved for influenza prevention and patients under 5 years old in China. Due to the long half-life of the drug, it only needs to be taken once throughout the whole process, which is more convenient to use.
In 2021, mabaloxavir (trade name: Sufuda) was approved for marketing in China, and the marketing authorization holder is Roche Pharmaceutical (Switzerland) Company. According to public information, baloxavir was first developed by the Japanese pharmaceutical company Shionogi, and Roche Pharmaceutical reached a cooperation with the Japanese pharmaceutical company Shionogi in 2016 to jointly develop the mabaloxavir market.
However, it is worth noting that Sufuda was previously only approved for the use of patients aged 12 years and above with uncomplicated influenza A and B. On March 21, 2023, Sufuda was approved for use in patients with pre-existing health and children aged 5 years and older with uncomplicated influenza A and B, or influenza patients at high risk of influenza-related complications and children aged 12 years and older.
Doctor: The patient must be up to 5 years old
Weigh more than 20 kg
On December 16, Song Chunlan, director of the emergency department of the South Branch of Henan Provincial Children's Hospital, said that judging from the current situation in the hospital, there are indeed doctors who prescribe oral mabaloxavir for suitable children with influenza.
Song Chunlan said that mabaloxavir is an influenza virus RNA polymerase inhibitor and is a new type of anti-influenza virus drugAt present, it has been approved for use in patients aged 5 years and above with confirmed influenza in China, and the applicable patient group of the drug is limited, and it can be used without a common cold.
Mabaloxavir is a medicine for older children diagnosed with influenza and requires patients aged five years and weighing more than 20 kilograms. Compared with other anti-influenza drugs, mabaloxavir only needs to be taken once, and studies have shown that it can stop influenza virus detoxification within 24 hours, shorten the influenza infectious period, have good safety, and can quickly alleviate clinical symptoms, stop virus detoxification, and reduce complications in high-risk groups, but when taking, we must pay attention to clinical indications, dosage, and whether there are allergic reactions and other precautions. Song Chunlan said.
According to the Yangtze Evening News, Yan Simin, director of the Department of Pharmacy of Nanjing Drum Tower Hospital, remindedSpecial populations such as pregnant women, patients with severe hepatic insufficiency, and renal insufficiency (creatinine clearance less than 50 mL min) should be avoided as much as possible. Even mild hepatic and renal insufficiency should be used under the guidance of a medical professional. Patients should try to avoid taking these drugs if they are taking some drugs that contain cationic ingredients, or some drugs that contain iron, zinc, calcium, magnesium, etc., and those who need to use dairy products.
*: People's ** client, Red Star News.